The ability of linezolid to combat skin and soft tissue infections was previously assessed in a randomized trial that compared the use of linezolid to aminopenicillin–beta-lactamase inhibitor products for the treatment of foot infections in patients living with diabetes [18]. Here, LACTB is linked to diabetes mellitus.